Liftstream is an executive search recruitment company in the life sciences sector
Immunocore Hires Senior Members and Launches US Office
Immunocore, a biotechnology company developing novel T cell receptor (TCR) based biological drugs to treat cancer, viral infections and autoimmune disease, has appointed James Sandy as Chief Development Officer and Julian Hirst as Director of Corporate Finance. These new positions will be based in the firm’s headquarter in Oxford, UK.
Top 5 Articles from Liftstream Blog in 2015
These are the 5 articles most viewed this year…so here is a recap for your to dive back in and read what you missed.
VCs Listening to Pitches for Age-related Diseases
Author: Karl Simpson
European biotech industry sees success and optimism rise over new Horizon
Authored by Karl Simpson
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business Tagged Alzheimer, Alzheimers, Barry Kenny, Belgium, CD38, celgene, Clarus Ventures, complix, DMD, Drisapersen, Duchenne Muscular Dystrophy, EU commission, europe, European biotech, FP7 programme, Genentech, Genmab, Heptares, Horizon 2020 programme, ImmTAC, Immunocore, IPO, J&J, Johnson & Johnson, MOR202, Morphosys, myeloma, Oxford, Prosensa, Stanley Family Foundation, Takeda, Takeda Ventures, Weekly review Leave a comment